Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Assets: 2017-2025

Historic Non-Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $74.8 million.

  • Crinetics Pharmaceuticals' Non-Current Assets rose 25.04% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year increase of 25.04%. This contributed to the annual value of $59.2 million for FY2024, which is 3.26% down from last year.
  • Crinetics Pharmaceuticals' Non-Current Assets amounted to $74.8 million in Q3 2025, which was up 3.38% from $72.3 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Non-Current Assets registered a high of $74.8 million during Q3 2025, and its lowest value of $5.0 million during Q1 2022.
  • Its 3-year average for Non-Current Assets is $54.7 million, with a median of $60.9 million in 2024.
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Non-Current Assets declined by 14.44% in 2021 and then skyrocketed by 903.16% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Non-Current Assets (Quarterly) stood at $6.3 million in 2021, then grew by 11.07% to $7.0 million in 2022, then soared by 775.29% to $61.2 million in 2023, then declined by 3.26% to $59.2 million in 2024, then climbed by 25.04% to $74.8 million in 2025.
  • Its Non-Current Assets stands at $74.8 million for Q3 2025, versus $72.3 million for Q2 2025 and $70.3 million for Q1 2025.